Physician profile
Timothy J Malins
NPI 1285742064
$779.09
in general payments reported to CMS, 2019-2025
15 companies · $326 in 2025
The $326 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23.08 · 2020: $11.24 · 2021: $82.43 · 2022: $14.71 · 2023: $128 · 2024: $193 · 2025: $326.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $648.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $647.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $300.78 | 2023-2025 | |
| Novo Nordisk INC | $77.12 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $57.83 | 2023-2025 | |
| Amgen INC. | $52.17 | 2025 | Repatha |
| Irhythm Technologies, INC. | $42.43 | 2021 | |
| Edwards Lifesciences Corporation | $41.63 | 2025 | Pascal |
| Vifor Pharma, INC. | $40.00 | 2021 | |
| Scpharmaceuticals INC. | $32.96 | 2025 | |
| Janssen Pharmaceuticals, INC | $31.27 | 2020-2024 | Xarelto |
| Biotronik INC. | $23.08 | 2019 | |
| Abiomed | $19.57 | 2025 | |
| Lexicon Pharmaceuticals, INC. | $17.46 | 2023 | Inpefa |
| Sanofi-Aventis U.S. LLC | $14.71 | 2022 | |
| Lilly USA, LLC | $14.58 | 2025 | Mounjaro |
| Esperion Therapeutics, INC. | $13.50 | 2025 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Malins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.